Bone morphogenetic protein receptor type-2
Description:
| Description |
|---|
|
Drug Relations:
|
bosutinib
|
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases | Bioactivity details | MOA |
|
|
nintedanib
|
Bioactivity details | MOA |
|
|
|
ruxolitinib
|
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19. | Bioactivity details | MOA |
|
|
sunitinib
|
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA. | Bioactivity details | MOA |
|